Title : Integrating personalized and precision medicine into dermatology clinical practice Securing ITS potential to get skin diseases cured and to revolutionize dermatology
Abstract:
Personalized & Precision Medicine (PPM) - driven dermatology uses individualized dermatologic disease-directed targeted therapy for the management of dermatoses and for the evaluation and therapy of cutaneous malignancies. For instance, the pathologic diagnosis of a pigmented lesion and determining the prognosis of a malignant melanocytic neoplasm can be enhanced by genomic/transcriptomic analysis.
The other example is psoriasis, when choosing a biologic medication for the disorder often relies on patient preference, provider preference, and a trial-and-error approach. Utilizing PPM-based tests, we can help providers identify biomarkers unique to a patient’s pathophysiology and choose the optimal targeted medication through a targeted and evidence-based approach. Among psoriasis-specific biomarkers and thus modes of targeted therapy, most of the latter discovered and designed focused on anti-TNF and IL12/23, with still few on IL17 (secukinumab). So, PPM-driven treatment in psoriasis would provide excellent outcome minimizing the risk of side effects.
It would be extremely useful to integrate available scientific knowledge on skin disorders-associated abnormal genes and gene products and their implications for targeted therapy! And thus data harvesting from different databanks for applications to thus provide more tailored measures for the patients resulting in improved patient outcomes, reduced adverse events, and more cost effective use of the latest health care resources including diagnostic (companion ones), preventive and therapeutic (targeted molecular and cellular) etc. The latter requires the incorporation of information from multiple data sources, linking the functional effects of altered genes to potential therapy options into a central repository that can be easily accessed, interpreted, and utilized by physicians and patients.
But! For many dermatological conditions, there is a lack of standardized methodology for quantitatively tracking disease progression and treatment response. And new tools using digital health technology can aid in capturing the variables over time. With these data, machine learning can inform efforts to improve health care by, for example, the identification of high-risk patient groups, optimization of treatment strategies, and prediction of disease outcomes.
The advent of PPM in dermatology could lead to a paradigm shift in how patients are treated, with the resulting improved clinical outcomes leading to concomitant reductions in wasted healthcare expenditures. We are entering an era of rapidly evolving transformation in skin pathology-related research as it relates to medical practice, and a shifting paradigm of standardized health care in which detailed genetic and molecular information regarding a patient’s cancer is being used for PPM-based treatments.
Coordination of all health care stakeholders has become more important than ever to unite dermatologists, pathologists, immunologists, geneticists, and payers to work with Big Pharma and Biotech to develop products, services, and coverage policies that would improve patient outcomes and lower overall health care costs for institutions that put personalized regimens in place. This is the reason for developing global scientific, clinical, social, and educational projects in the area of PPM dermatology to elicit the content of the new branch and to stress the impact and benefits of the latter.
